Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 279

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 279
---
 are issued, which may affect,                                                            
 among other things, Kineta’s ability to use its NOL carry forwards, if any, and could result in the resignation or removal of Kineta’s present officers and directors; and |

| • |     | may adversely affect prevailing market prices for the common stock. |

Kineta Common Stock trades on an over-the-countermarket, which has adversely affected its stock price and the liquidity of its stock and could impact its ability to obtain financing could be impaired. Kineta’s common stock was suspended from trading on The Nasdaq Capital Market at the opening of business on September 19, 2024 and delisted from Nasdaq effective as of October 25, 2024. Since September 19, 2024, Kineta Common Stock has been trading on the OTC Pink Market under the symbol “KANT.” Such market is currently the only trading market for Kineta Common Stock, which subjects Kineta and its stockholders to certain significant risks including:

| • |     | limited availability of market quotations for Kineta Common Stock; |

| • |     | reduced liquidity for Kineta Common Stock, including reduced availability of buyers or sellers of Kineta Common 
 Stock;                                                                                                          |

| • |     | limited amount of news and analyst coverage or no coverage at all; |

| • |     | decreased ability to issue additional securities or obtain additional financing in the future; and |

171

| • |     | Kineta Common Stock is no longer a “covered security” under the National Securities Markets Improvement 
 Act of 1996, and therefore subject to regulation in each state in which Kineta offer securities.        |

Kineta can provide no assurance that its common stock will continue to trade on this market or any other market, whether broker-dealers will continue to provide public quotes of Kineta Common Stock on this market, whether the trading volume of Kineta Common Stock will be sufficient to provide for an efficient trading market or whether quotes for Kineta Common Stock will continue on this market in the future, which could result in significantly lower trading volumes and reduced liquidity for investors seeking to buy or sell Kineta Common Stock. The ability of Kineta’s investors to access the capital markets may be severely limited or eliminated. Because of the trading volatility often associated with low-pricedstocks not listed on a national securities exchange, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-pricedstocks or tend to discourage individual brokers from recommending low-pricedstocks to their customers